The most recent report from The Lancet Commissio
Author: Michael
Are you among the 159 million Americans who drin
Longevity.
Obesity presents a major global health challenge
Longevity world mourns a pioneer of aging resear
Company targets Phase 2 trial of oral Alzheimer’s drug that inhibits the activity of microglia to combat neuroinflammation. US biotech NeuroTherapia has secured $12.3 million in the first close of a Series B financing round to progress its mission to tackle central nervous system diseases, with an initial focus on Alzheimer’s. While many companies are targeting the removal of toxic proteins like beta amyloid, tau and alpha synuclein, the Cleveland Clinic spinout is addressing neuroinflammation, a factor increasingly recognized as crucial in the progression of CNS diseases. NeuroTherapia’s focus is on developing orally available small-molecule drugs that inhibit the activity…
In recent years, a staggering 50% decrease in ni